Expert interprets FDA guidance on social media

01/9/2012 | Wall Street Journal, The

Drugmakers should be cautious when soliciting patient testimonials because discussions of off-label use could run afoul of recent FDA guidance, says Dale Cooke, vice president and group director of regulatory review at marketing shop Digitas Health. Drugmakers should also be careful with blogging about clinical trials tied to unapproved uses and ensure that conversations about off-label uses are not in a public forum, he said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD